Keylika
ActiveRedefining the Standard of Care for Iron Deficiency Anemia
About
Keylika is an early stage biopharma startup developing metal-based drugs using a platform synthesis technology to treat unmet medical needs. We then administer these drugs using proven delivery technologies to effect the best clinical outcomes. Our first product is a small molecule iron drug (new molecular entity) delivered by a wearable skin patch to treat Iron Deficiency Anemia (IDA), with significantly higher safety, efficacy and tolerability over existing treatments. This is poised to be a best-in-class, potentially breakthrough therapy for treating iron deficiency without any GI side-effects (eg. nausea, constipation, diarrhea, etc.) typically associated with oral iron supplements, and without the risks, costs and side-effects associated with IV iron infusions. When approved, Keylika’s proprietary transdermal iron will be the world's first prescription iron patch. Iron deficiency is a hugely understated problem affecting about 1.6 billion people worldwide and more than 30 million in the US alone, translating to a $17B US market.
Founders · 2
Buddha spearheaded the technology development of a microneedle-based biosensor from lab-to-fab for a Series B stage medtech startup. Having worked across 3 continents and 6 countries, he has been instrumental in developing novel healthcare technologies in leading global research institutes and biotech companies, for the last 15 years. Buddha earned his PhD from Imec / KU Leuven in Belgium, in Drug Delivery Microsystems. He also pursued a Postdoc at UC San Francisco (UCSF) / UC Berkeley.
With a deep passion for diverse technologies, Frederik is truly a multi-domain expert. From tiny moving machines to nuclear space rockets, and electrical circuits to medical devices – Frederik has pursued an illustrious scientific career over the last 15 years developing key microtechnologies for lifescience applications. He also founded a venture-backed neurotech startup to cure blindness. Frederik holds a PhD and a Masters in IC design as well as a Bachelors' in Medicine.
Related startups
Platform injectable gel based therapeutic for osteoarthritis
KemNet supplies reformulated drugs for specific groups of patients.
